-
Mashup Score: 0
This breakthrough therapy designation of ziftomenib marks the first of its kinds in NPM1-mutant acute myeloid leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia - 1 month(s) ago
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15
Ponatinib in combination with chemotherapy is now an approved treatment option for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
The #FDA has granted a breakthrough therapy designation to ziftomenib for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia. #LEUSM https://t.co/vzN990k5UI